Thomas Chalberg

Thomas Chalberg is a board member at Chameleon Biosciences. Thomas is also the founder, CEO, and chief scientific officer at SightGlass Vision, Inc. where they have delivered innovative, science-based treatments addressing the myopia pandemic to children around the world. In 2021, they sold SightGlass Vision to a joint venture between CooperVision and EssilorLuxottica. Prior to founding SightGlass Vision, Chalberg served as the Chief Operating Officer (interim) at Oncorus, Inc., an immuno-oncology company developing the next generation of oncolytic vectors.

Chalberg's career in the biotechnology industry began at Genentech where they spent 4 years 11 months in marketing and commercial operations for ophthalmology and oncology before becoming a biotechnology consultant at ZS Associates for 4 years 1 month. In 2009, Chalberg founded Avalanche Biotechnologies, Inc (now Adverum; NASDAQ: ADVM), a leader in gene therapy for eye diseases. At Avalanche Biotechnologies/Adverum, Chalberg built a platform for the discovery, development, and manufacturing of adeno-associated vectors (AAV) for retinal disease.

Thomas Chalberg has a PhD from Stanford University School of Medicine in Cancer Biology, Genetics, and Ophthalmology, which they received in 2005. Thomas also has an MBA from the University of California, Berkeley - Walter A. Haas School of Business, which they received in 2011. Prior to that, they attended Harvard University, where they received an A.B. in Biochemical Sciences in 1999. Thomas also went to Campolindo High School, where they were the State of California CIF Scholar-Athlete of the Year in 1995.